309 related articles for article (PubMed ID: 15494686)
1. Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation.
Siragusa S; Anastasio R; Giarratano A; Malato A; Bonifacio G; Arcara C; Gebbia N
Exp Oncol; 2004 Sep; 26(3):192-5. PubMed ID: 15494686
[TBL] [Abstract][Full Text] [Related]
2. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.
Siragusa S; Anastasio R; Porta C; Falaschi F; Pirrelli S; Palmieri P; Gamba G; Granzow K; Malato A; Minardi V; Tatoni P; Bressan MA; Mariani G
Arch Intern Med; 2004 Dec 13-27; 164(22):2477-82. PubMed ID: 15596639
[TBL] [Abstract][Full Text] [Related]
3. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
4. Extensive evaluation of the instrumentation laboratory IL test D-Dimer immunoturbidimetric assay on the ACL 9000 determines the D-Dimer cutoff value for reliable exclusion of venous thromboembolism.
Curtin N; Highe G; Harris M; Braunstein A; Demattia F; Coss L
Lab Hematol; 2004; 10(2):88-94. PubMed ID: 15224764
[TBL] [Abstract][Full Text] [Related]
5. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism: risk factors for recurrence.
Zhu T; Martinez I; Emmerich J
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
[TBL] [Abstract][Full Text] [Related]
8. Value of D-dimer testing for the exclusion of pulmonary embolism in patients with previous venous thromboembolism.
Le Gal G; Righini M; Roy PM; Sanchez O; Aujesky D; Perrier A; Bounameaux H
Arch Intern Med; 2006 Jan; 166(2):176-80. PubMed ID: 16432085
[TBL] [Abstract][Full Text] [Related]
9. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of patients hospitalized with venous thromboembolism: comparison between cancer and non-cancer patients.
Kolomansky A; Hoffman R; Sarig G; Brenner B; Haim N
Isr Med Assoc J; 2006 Dec; 8(12):848-52. PubMed ID: 17214102
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J; Goodin S
J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
[TBL] [Abstract][Full Text] [Related]
12. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
[TBL] [Abstract][Full Text] [Related]
13. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
Noble SI; Hood K; Finlay IG
Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086
[TBL] [Abstract][Full Text] [Related]
14. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.
Cunningham RS
Semin Oncol; 2006 Apr; 33(2 Suppl 4):S17-25; quiz S41-2. PubMed ID: 16638457
[TBL] [Abstract][Full Text] [Related]
15. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
16. Managing suspected venous thromboembolism in a mixed primary and secondary care setting using standard clinical assessment and D-dimer in a noninvasive diagnostic strategy.
de Bastos MM; Bastos MR; Pessoa PC; Bogutchi T; Carneiro-Proietti AB; Rezende SM
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):48-54. PubMed ID: 18180615
[TBL] [Abstract][Full Text] [Related]
17. D-dimer testing in the diagnosis of acute venous thromboembolism.
Brill-Edwards P; Lee A
Thromb Haemost; 1999 Aug; 82(2):688-94. PubMed ID: 10605769
[TBL] [Abstract][Full Text] [Related]
18. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
19. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
